Ultime notizie per Owens & Minor (NYSE:OMI) Azioni

Owens & Minor

Owens & Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products & Healthcare Services and Patient Direct. The Products & Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products & Healthcare Services segment.

Earnings

News

Pre-Market Outlook

Markets

Trading Ideas

DELL

GTLS

Giornata cruciale sui mercati: quali dinamiche guideranno le scelte degli investitori? Ecco i titoli da monitorare oggi.

Affari in vista? HP, Dell e 3 titoli da monitorare per un venerdì da protagonisti

Owens & Minor Inc

Singular Genomic Systems Inc COM NEW

Omid Holdings Inc

OMINECA MINING & MTLS ORD by Omineca Mining & Metals Ltd.

Omineca Mining and Metals Ltd

OmiseGO - United States Dollar

WIIM

Owens & Minor shares are trading lower after the company reported worse-than-expected Q1 sales results

U.S. stocks rallied Thursday after the Trump administration signed its first major trade agreement with the United Kingdom, igniting optimism about further global deals — especially with China — and lifting investor <a href="https://www.benzinga.com/markets">appetite for riskier assets.</a>
The S&amp;P 500 jumped 1.3% to close at 5,700, led by gains in technology stocks. The Russell 2000 soared 2.1%, outperforming larger-cap counterparts and fully recovering the losses triggered by the April 2 tariff announcement.
Under the deal, the U.S. slashed tariffs on UK-made vehicles from 25% to 10%, granting British carmakers a 100,000-vehicle quota. In return, the UK reduced tariffs on American beef to near-zero levels and pledged to purchase $10 billion worth of Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>) aircraft. Trump confirmed that the 10% tariff would remain the baseline for now, though he suggested other nations with large trade surpluses should expect higher rates.
During a press briefing, Trump hinted at the &#8220;biggest tax cuts in history&#8221; and urged investors to act: "You better go out and buy stock. This country will be like a rocket ship," he said.
The president also responded to Federal Reserve Chair Jerome Powell, who noted a day earlier he hadn't been invited to meet with Trump. "I could call him from a meeting, but it's like talking to a wall," Trump said. 
"He's always too late [in cutting interest rates]. But in this case, it's not going to matter that much because our country is so strong."
Markets reflected that strength. The U.S. dollar rallied sharply as the new trade deal and reduced economic uncertainty boosted confidence. The U.S. Dollar Index (DXY) jumped to its highest level since April 11, climbing over 1% against the Japanese yen.
Treasury yields rose across the curve, with the 10-year yield adding 7 basis points to reach 4.34%.
In commodities, gold prices dropped as investors rotated out of safe havens. The SPDR Gold Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLD#NYSE">GLD</a>) fell 1.5%, trimming its weekly gains. Oil prices rose 3.5%, with West Texas Intermediate crude topping $60 per barrel.
Crypto markets erupted higher. Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) broke above $100,000 for the first time since February, rising 4.1%. Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) surged 13%, while Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) gained 10%.
<h3 class="wp-block-heading">Thursday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices</td>
<td>Price</td>
<td>1-day % Chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,030.85</td>
<td>+2.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>20,218.21</td>
<td>+1.8%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>41,683.40</td>
<td>+1.4%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,707.58</td>
<td>+1.3%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated by 12:10 p.m. ET</figcaption></figure>
According to&nbsp;<a href="https://www.benzinga.com/pro/?utm_source=BZprocontent&amp;t=be2bearmibe3na1">Benzinga Pro</a>&nbsp;data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) rallied 1.4% to $569.13.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>) rose 1.4% to $416.94.</li>
<li>The tech-heavy&nbsp;Invesco QQQ Trust Series&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>)&nbsp;rallied 1.8% to $491.78.</li>
<li>The&nbsp;iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) soared 2.2% to $201.78.</li>
<li>The&nbsp;Energy&nbsp;Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLE#NYSE">XLE</a>) outperformed, up 2.5%; the&nbsp;Health Care&nbsp;Select Sector SPDR Fund&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLV#NYSE">XLV</a>) lagged, down 0.4%.</li>
</ul>
<h3 class="wp-block-heading">Thursday&#8217;s Stock Movers</h3>
Stocks reacting to earnings reports included: 
<ul>
<li>Fortinet Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTNT#NASDAQ">FTNT</a>) down 9.5%</li>
<li>Axon Enterprise Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) down 0.6%</li>
<li>Corteva Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CTVA#NYSE">CTVA</a>) up 6.2%</li>
<li>Occidental Petroleum Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OXY#NYSE">OXY</a>) up 6.3%</li>
<li>Texas Pacific Land Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPL#NYSE">TPL</a>) up 1.5%</li>
<li>Atmos Energy Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATO#NYSE">ATO</a>) up 0.6%</li>
<li>Fidelity National Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FNF#NYSE">FNF</a>) down 7.0%</li>
<li>Western Gas Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WES#NYSE">WES</a>) up 2.9%</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) down 1.85%</li>
<li>ConocoPhillips (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COP#NYSE">COP</a>) up 4.30%</li>
<li>Canadian Natural Resources Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNQ#NYSE">CNQ</a>) up 4.93%</li>
<li>Cheniere Energy, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNG#NYSE">LNG</a>) up 0.79%</li>
<li>Sempra (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SRE#NYSE">SRE</a>) up 0.83%</li>
<li>Cenovus Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVE#NYSE">CVE</a>) up 8.87%</li>
<li>Tapestry, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPR#NYSE">TPR</a>) up 4.26%</li>
<li>Molson Coors Beverage Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAP#NYSE">TAP</a>) down 3.44%</li>
<li>Lincoln National Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LNC#NYSE">LNC</a>) down 0.60%</li>
<li>PENN Entertainment, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PENN#NASDAQ">PENN</a>) up 1.64%</li>
<li>Hanesbrands Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HBI#NYSE">HBI</a>) up 5.21%</li>
<li>Spectrum Brands Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPB#NYSE">SPB</a>) up 3.81%</li>
<li>Global Partners LP (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLP#NYSE">GLP</a>) down 2.15%</li>
<li>NCR Voyix Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VYX#NYSE">VYX</a>) up 15.14%</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) down 7.16%</li>
</ul>
Stocks slated to report earnings after the close include Akamai Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AKAM#NASDAQ">AKAM</a>), Expedia Group, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXPE#NASDAQ">EXPE</a>), Microchip Technology Incorporated (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>), McKesson Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MCK#NYSE">MCK</a>), and News Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWSA#NASDAQ">NWSA</a>).
Read now: 
<ul>
<li><a href="https://www.benzinga.com/politics/25/05/45293839/trump-starmer-strike-us-uk-trade-deal-steel-cars-beef">Trump, Starmer Strike US-UK Trade Deal: Steel, Cars, Beef At Center Of Pact</a></li>
</ul>

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Equities

Large Cap

Macro Economic Events

Mid Cap

Sector ETFs

Bonds

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

Tech

ETFs

$BTC

$DOGE

$ETH

AKAM

AXON

CTVA

SPDR Dow Jones Industrial Average ETF Trust

EXPE

FTNT

MCHP

NWSA

PENN

SHOP

Select Sector SPDR-Consumer Discretionary

Wall Street Rallies After US Seals First Trade Deal: 'You Better Go Out And Buy Stock,' Trump Says

Owens &amp; Minor Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported first-quarter 2025 adjusted EPS of 23 cents, up from 19 cents a year ago, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of 20 cents</a>.
The company reported sales of $2.63 billion, which were almost flat year over year and missed the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/b45279832/owens-minor-reports-first-quarter-2025-financial-results" rel="noreferrer noopener">consensus of $2.66 billion</a>.
Products &amp; Healthcare Services revenue of $1.96 billion, down 1%. Patient Direct revenue of $673.8 million, up 6% year-over-year.
In February, the company said Citi would serve as its exclusive financial advisor regarding the potential sale of the Products &amp; Healthcare Services segment.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45157863/cardinal-health-lifts-fy25-eps-outlook-sees-growth-despite-tariff-risks" rel="noreferrer noopener">Cardinal Health Lifts FY25 EPS Outlook, Sees Growth Despite Tariff Risks</a>
The company reported adjusted operating income of $61.3 million, up from $57.4 million. Adjusted EBITDA increased from $116.3 million to $121.9 million.
The Products &amp; Healthcare Services segment saw top-line growth in medical distribution, according to CEO Edward Pesicka.
&#8220;We remain actively engaged in the sale process of our Products &amp; Healthcare Services segment," he added.
Pesicka concluded, "Looking ahead, our focus remains on disciplined capital deployment, working towards our leverage target, successfully navigating potential changes in government policy, including tariffs and integrating our planned acquisition of Rotech. We remain bullish on the outlook for our Patient Direct segment and the strengthening of our P&amp;HS businesses."
Guidance:&nbsp;Owens &amp; Minor <a target="_blank" href="https://www.benzinga.com/25/02/44044604/healthcare-logistics-giant-owens-minor-reports-better-than-expected-q4-earnings-and-outlook-to-repurchase-100-million-worth-shares" rel="noreferrer noopener">reaffirmed fiscal 2025</a> adjusted earnings per share guidance of $1.60-$1.85 versus the consensus of $1.67.
The company forecasts 2025 sales of $10.85 billion-$11.15 billion compared to the consensus of $11.05 billion.
The company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, the Products &amp; Healthcare Services segment, or tariffs.
The healthcare logistics&nbsp;company expects adjusted EBITDA for 2025 to be $560 million to $590 million.
Price Action: Owens &amp; Minor&#8217;s stock is down 7.86% at $7.15 at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/05/45285163/groupon-q1-billings-sees-double-digit-growth-in-north-america-guides-q2-above-consensus" target="_blank" rel="noreferrer noopener">Groupon Posts Surprise Q1 Profit, Raises Annual Outlook</a></li>
</ul>
Image: Shutterstock

Guidance

Health Care

Movers

General

Why Is Owens & Minor Stock Trading Lower On Thursday?

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) affirms FY2025 Adj EPS guidance from $1.60-$1.85 to $1.60-$1.85 vs $1.67 analyst estimate. Affirms FY2025 sales outlook from $10.85 billion-$11.15 billion to $10.85 billion-$11.15 billion vs $11.05 billion estimate.

Owens & Minor Affirms FY2025 Adj EPS Guidance of $1.60-$1.85 vs $1.67 Est; Affirms FY2025 Sales Guidance of $10.85B-$11.15B vs $11.05B Est

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported quarterly earnings of $0.23 per share which beat the analyst consensus estimate of $0.20 by 15 percent. This is a 21.05 percent increase over earnings of $0.19 per share from the same period last year. The company reported quarterly sales of $2.63 billion which missed the analyst consensus estimate of $2.66 billion by 0.99 percent. This is a 0.73 percent increase over sales of $2.61 billion the same period last year.

Earnings Beats

Earnings Misses

Owens & Minor Q1 Adj. EPS $0.23 Beats $0.20 Estimate, Sales $2.63B Miss $2.66B Estimate

AAOI

ABCL

ABEV

ACIC

ACIW

ACMR

ACTG

AFRM

AKBA

ALGM

ALIT

ALRM

ALXO

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

AMPX

AMTX

APPN

APYX

AQMS

ARGX

ARHS

ARKO

ARLO

ASPN

ASTH

Adtalem Global Education Inc. Common Stock

ATGE

ATHM

ATUS

AUTL

AVAH

AVPT

AXGN

BAER

BBDC

BIGC

BILL

BIRD

BlackSky Technology Inc. Class A Common Stock

BKSY

BLFS

BLND

CARG

CARS

CBLL

CBUS

CCEC

CCOI

CCRD

CDTX

CION

CLAR

CLFD

CLNE

CLSK

CMPS

CMRE

CODX

COIN

COLD

COLL

COMP

CRNX

CRON

CROX

CRVS

CTEV

CTKB

CTLP

CVRX

DAVE

DCGO

DCTH

DIOD

DKNG

Earnings Scheduled For May 8, 2025

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) is set to give its latest quarterly earnings report on Thursday, 2025-05-08. Here's what investors need to know before the announcement.
Analysts estimate that Owens &amp; Minor will report an earnings per share (EPS) of $0.20. 
Anticipation surrounds Owens &amp; Minor's announcement, with investors hoping to hear about both surpassing estimates and receiving positive guidance for the next quarter.
New investors should understand that while earnings performance is important, market reactions are often driven by guidance.
<h3>Overview of Past Earnings</h3>
During the last quarter, the company reported an EPS beat by $0.03, leading to a 0.0% drop in the share price on the subsequent day.
Here's a look at Owens &amp; Minor's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.52</td>
<td>0.41</td>
<td>0.31</td>
<td>0.17</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.55</td>
<td>0.42</td>
<td>0.36</td>
<td>0.19</td>
</tr>
<tr>
<td>Price Change %</td>
<td>39.0%</td>
<td>-2.0%</td>
<td>-1.0%</td>
<td>-26.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746630108_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Owens &amp; Minor were trading at $7.71 as of May 06. Over the last 52-week period, shares are down 57.29%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<h3>Analyst Insights on Owens &amp; Minor</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Owens &amp; Minor.
The consensus rating for Owens &amp; Minor is Buy, derived from 5 analyst ratings. An average one-year price target of $11.0 implies a potential 42.67% upside.
<h3>Comparing Ratings Among Industry Peers</h3>
This comparison focuses on the analyst ratings and average 1-year price targets of and Owens &amp; Minor, three major players in the industry, shedding light on their relative performance expectations and market positioning.
<h3>Peer Analysis Summary</h3>
In the peer analysis summary, key metrics for and Owens &amp; Minor are highlighted, providing an understanding of their respective standings within the industry and offering insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Owens &amp; Minor</td>
<td>Buy</td>
<td>1.50%</td>
<td>$579.77M</td>
<td>-41.13%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Owens &amp; Minor ranks at the bottom for Revenue Growth among its peers, with a growth rate of 1.50%. It also lags behind in Gross Profit, standing at $579.77M. Additionally, its Return on Equity is at -41.13%, indicating poor performance in this metric compared to its peers.
<h3>Unveiling the Story Behind Owens &amp; Minor</h3>
Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products &amp; Healthcare Services and Patient Direct. The Products &amp; Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products &amp; Healthcare Services segment.
<h3>Understanding the Numbers: Owens &amp; Minor's Finances</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Owens &amp; Minor displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 1.5%. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Owens &amp; Minor's net margin is impressive, surpassing industry averages. With a net margin of -10.98%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Owens &amp; Minor's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of -41.13%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Owens &amp; Minor's ROA excels beyond industry benchmarks, reaching -6.08%. This signifies efficient management of assets and strong financial health.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 3.79.
<a href="https://www.benzinga.com/quote/OMI/earnings">To track all earnings releases for Owens &amp; Minor visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For Owens & Minor

Citigroup analyst Daniel Grosslight maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Buy and lowers the price target from $13 to $11.

Price Target

Analyst Ratings

Citigroup Maintains Buy on Owens & Minor, Lowers Price Target to $11

The Offering is expected to close on April 4, 2025, subject to customary closing conditions. The Notes will bear interest at the rate of 10.000% per year.&nbsp;
The Notes will mature on April 15, 2030 (subject to certain earlier maturity triggers). The Notes were offered at a price of 100% of their principal amount.

Offerings

Owens & Minor Reports Upsize And Pricing Of $1B Senior Secured Notes Offering

Owens & Minor Launches Private Offering Of $600M Of Senior Secured Notes Due 2030

U.S. stock futures were higher this morning, with the Dow futures gaining around 200 points on Wednesday.
Shares of Hello Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MOMO#NASDAQ">MOMO</a>) fell sharply during pre-market trading after reporting weak quarterly results.
Hello Group posted fourth-quarter adjusted EPADS of 18 cents missing estimates of 21 cents per shares. The company's sales came in at $361.20 million missing expectations of $365.05 million.
Hello Group shares dipped 12.4% to $6.50 in the pre-market trading session.
Here are some other stocks moving lower in pre-market trading.
<ul>
<li>Lazard, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LAZ#NYSE">LAZ</a>) dipped 13% to $40.00 in pre-market trading after the company reported February assets under management.</li>
<li>loanDepot, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LDI#NYSE">LDI</a>) shares fell 10.4% to $1.44 in pre-market trading after the company reported worse-than-expected fourth-quarter revenue results and a year-over-year decrease in adjusted EPS results.</li>
<li>Amylyx Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMLX#NASDAQ">AMLX</a>) fell 9.9% to $3.36 in today's pre-market trading after gaining 7% on Tuesday.</li>
<li>Mineralys Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLYS#NASDAQ">MLYS</a>) fell 8.3% to $13.10 in pre-market trading. Mineralys Therapeutics priced its $175 million public offering of 12,962,962 common shares at $13.50/share.</li>
<li>MaxCyte, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MXCT#NASDAQ">MXCT</a>) slipped 7.2% to $3.22 in pre-market trading following quarterly earnings.</li>
<li>XPeng Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XPEV#NYSE">XPEV</a>) fell 6.2% to $24.72 in pre-market trading. XPeng shares jumped around 15% on Tuesday after the company announced to spend up to $13.8 billion on humanoid robots.</li>
<li>Owens &amp; Minor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) shares dipped 3.1% to $9.25 in pre-market trading. Owens &amp; Minor recently reported better-than-expected quarterly financial results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44245496/top-3-health-care-stocks-that-may-keep-you-up-at-night-in-q1">Top 3 Health Care Stocks That May Keep You Up At Night In Q1</a></li>
</ul>

MLYS

MOMO

MXCT

XPEV

Hello Group, loanDepot, Mineralys Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session

Providing a diverse range of perspectives from bullish to bearish, 5 analysts have published ratings on Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) in the last three months.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $11.6, a high estimate of $14.00, and a low estimate of $10.00. Experiencing a 25.64% decline, the current average is now lower than the previous average price target of $15.60. 
<img src="https://www.benzinga.com/files/images/story/2025/1741644335_0.png" alt="price target chart" />
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
The standing of Owens &amp; Minor among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Michael Minchak</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$11.00</td>
<td>$10.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$10.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Kevin Caliendo</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$13.00</td>
<td>$25.00</td>
</tr>
<tr>
<td>Eric Coldwell</td>
<td>Baird</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$14.00</td>
<td>$15.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Owens &amp; Minor. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Owens &amp; Minor compared to the broader market.</li>
<li>Price Targets: Analysts provide insights into price targets, offering estimates for the future value of Owens &amp; Minor's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Capture valuable insights into Owens &amp; Minor's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/OMI/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Owens &amp; Minor analyst ratings.</a>
If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">you can start by tracking it here</a>.
<h2>Delving into Owens &amp; Minor's Background</h2>
Owens &amp; Minor Inc distributes consumable medical supplies to a variety of providers. The business is under two segments: Products &amp; Healthcare Services and Patient Direct. The Products &amp; Healthcare Services segment manufactures and sources medical surgical products through its production and kitting operations and provides medical supplies and solutions for the prevention of healthcare-associated infections across the acute and alternate site channels. The Patient Direct segment provides delivery of disposable medical supplies sold directly to patients and home health agencies. Majority of the revenue is generated from Products &amp; Healthcare Services segment.
<h3>Owens &amp; Minor: Financial Performance Dissected</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Owens &amp; Minor's remarkable performance in 3 months is evident. As of 31 December, 2024, the company achieved an impressive revenue growth rate of 1.5%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of -10.98%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Owens &amp; Minor's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -41.13%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Owens &amp; Minor's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of -6.08%, the company may face hurdles in achieving optimal financial returns.
Debt Management: Owens &amp; Minor's debt-to-equity ratio is below the industry average. With a ratio of 3.79, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Demystifying Owens & Minor: Insights From 5 Analyst Reviews

JP Morgan analyst Michael Minchak maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Underweight and lowers the price target from $14 to $10.

JP Morgan Maintains Underweight on Owens & Minor, Lowers Price Target to $10

Baird analyst Eric Coldwell maintains Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) with a Neutral and raises the price target from $10 to $11.

Baird Maintains Neutral on Owens & Minor, Raises Price Target to $11

On Monday,&nbsp;Owens &amp; Minor Inc.&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported adjusted EPS of $0.45 for the fourth quarter of 2024, down from $0.69 a year ago but beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/calendars/earnings" rel="noreferrer noopener">consensus of $0.52</a>.
The company reported sales of $2.70 billion, up 1.5% year-over-year, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/25/02/b44038030/owens-minor-reports-fourth-quarter-full-year-financial-results-and-announces-sale-process-underway" rel="noreferrer noopener">consensus of $2.69 billion</a>.
Patient Direct revenue of $695.02 million, up 4.6% year-over-year.
Products &amp; Healthcare Services revenue of $2 billion increased marginally by 0.5%.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/25/02/43432128/owens-minor-stock-dips-on-mixed-q4-preliminary-results-310-million-apria-goodwill-charge-details" rel="noreferrer noopener">Owens &amp; Minor Stock Dips On Mixed Q4 Preliminary Results &amp; $310 Million Apria Goodwill Charge: Details</a>
The company reported fourth-quarter adjusted operating income of $95.4 million, down from $110.8 million. Adjusted EBITDA fell from $169.6 million to $138.21 million.
The company says Citi is serving as Owens &amp; Minor&#8217;s exclusive financial advisor regarding the potential sale of the Products &amp; Healthcare Services segment.
Owens &amp; Minor CEO Edward Pesicka said the company continues to leverage its footprint and broad product offering to support home-based care for millions of patients with chronic conditions. 
&#8220;These capabilities, combined with positive demographic trends and expanding home treatment options, leaves us very bullish on the future of this business,&#8221; Pesicka said. 
Owens &amp; Minor also repaid $647 million of debt over the last two years which helped with the company&#8217;s acquisition of Rotech, he added.
Pesicka added, "Our commitment to directing capital toward the higher growth and higher margin Patient Direct segment has been increasingly evident in recent years and is consistent with our strategy. As a logical next step, we have been actively engaged in robust discussions regarding the potential sale of our Products &amp; Healthcare Services segment."
Share Buyback: The Owens &amp; Minor Board of Directors authorized a share repurchase program of up to $100 million over the next 24 months.
Guidance:&nbsp;Owens &amp; Minor expects 2025 Revenues of $10.85 billion-$11.15 billion and adjusted EPS of $1.60-$1.85 versus consensus of $10.97 billion and $1.79, respectively.
The healthcare logistics&nbsp;company expects adjusted EBITDA for 2025 to be $560 million to $590 million.
Price Action:&nbsp;OMI stock is up 9.29% at $7.53 during the premarket session at the last check Friday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/health-care/25/02/44012867/sensodyne-toothpaste-maker-haleon-expects-profit-to-be-weighted-towards-second-half-of-2025" target="_blank" rel="noreferrer noopener">Sensodyne Toothpaste Maker Haleon Expects Profit To Be Weighted Towards Second Half Of 2025</a></li>
</ul>

Healthcare Logistics Firm Owens & Minor Reports Better-Than-Expected Q4 Earnings, Plans To Repurchase $100 Million In Shares

Owens & Minor shares are trading higher after the company reported better-than-expected Q4 financial results.

Owens & Minor Says Active Discussions Well Underway Regarding Potential Sale of Products & Healthcare Services Segment

2025 Financial Outlook
The Company issued its outlook for 2025; summarized below:
<ul>
<li>Revenue for 2025 to be in a range of $10.85 billion to $11.15 billion</li>
<li>Adjusted EBITDA for 2025 to be in a range of $560 million to $590 million</li>
<li>Adjusted EPS for 2025 to be in a range of $1.60 to $1.85</li>
</ul>
The Company's outlook for 2025 excludes any impact of the previously announced Rotech acquisition, any potential transaction involving the Products &amp; Healthcare Services segment, or share repurchase activity, and contains assumptions, including current expectations regarding the impact of general economic conditions.
Key assumptions supporting the Company's 2025 financial guidance include:
<ul>
<li>Gross margin of 20.75% to 21.25%</li>
<li>Interest expense of $138 million to $142 million</li>
<li>Adjusted effective tax rate of 29.0% to 30.0%</li>
<li>Diluted weighted average shares of ~80 million</li>
<li>Capital expenditures, gross, of $250 million to $270 million</li>
<li>Stable commodity prices</li>
<li>FX rates as of 12/31/2024</li>
</ul>

Owens & Minor Expects 2025 Revenues Of $10.85B-$11.15B And Adjusted EPS Of $1.60-$1.85 Versus Consensus Of $10.97B And $1.79, Respectively

Buybacks

Owens & Minor Authorizes Share Repurchase Program of Up to $100M

Owens &amp; Minor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OMI#NYSE">OMI</a>) reported quarterly earnings of $0.55 per share which beat the analyst consensus estimate of $0.52 by 5.77 percent. This is a 20.29 percent decrease over earnings of $0.69 per share from the same period last year. The company reported quarterly sales of $2.70 billion which beat the analyst consensus estimate of $2.69 billion by 0.39 percent. This is a 1.50 percent increase over sales of $2.66 billion the same period last year.

Owens & Minor Q4 2024 Adj EPS $0.55 Beats $0.52 Estimate, Sales $2.70B Beat $2.69B Estimate

Press Releases

Owens & Minor Launches ByramConnect Digital Health Platform for Diabetes and Other Chronic Health Conditions

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Owens & Minor, Inc. - OMI

Owens & Minor Reports Fourth Quarter & Full Year Financial Results and
Announces Sale Process Underway for Products & Healthcare Services Segment

Owens & Minor Announces Launch of Senior Secured Notes Offering

Owens & Minor Announces Upsize and Pricing of Senior Secured Notes Offering

Owens & Minor Announces Major Innovations to Products & Healthcare Services Network

Owens & Minor Announces First Quarter 2025 Earnings Release Date and Conference Call

Comments

Owens & Minor

Notizie

Ultime notizie per Owens & Minor (NYSE:OMI) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO